Educational guide
Chonluten Overview, Dosing & Safety | Peptide Database
Chonluten (EDG) EDG Tripeptide | Bronchial/Lung Bioregulator Community Research Join others researching Chonluten — share findings, ask questions, and learn from real experiences Chonluten is a Khavinson bioregulator tripeptide (EDG) derived from respiratory l
This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.
Chonluten (EDG)
EDG Tripeptide | Bronchial/Lung Bioregulator
Community Research
Join others researching Chonluten — share findings, ask questions, and learn from real experiences
Chonluten is a Khavinson bioregulator tripeptide (EDG) derived from respiratory lung tissue. Developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology, it targets the bronchopulmonary system with secondary activity in the GI tract. Research shows it regulates genes related to inflammation, antioxidant activity, and proliferation responses. Chonluten inhibits TNF production in monocytes and has been studied as a potential geroprotective agent that may support lung function in conditions like COPD.
Chonluten works through epigenetic regulation, penetrating cell and nuclear membranes to bind promoter or suppressor regions of DNA and modulate transcriptional control. It regulates genes including c-Fos, HSP70 (heat-shock protein), SOD (superoxide dismutase), COX-2, and TNF-alpha related to oxidative stress and proliferative regulation. The peptide inhibits TNF production in monocytes exposed to pro-inflammatory LPS, promoting attenuation of inflammatory action through TNF tolerance mechanisms.
Molecular Data
Glutamic Acid
Position 1
Aspartic Acid
Position 2
Glycine
Position 3
Research Indications
Normalizes respiratory system function through gene expression regulation.
Restores and maintains lung alveolar tissues and bronchial mucous membranes.
May modulate mucosal function in chronic obstructive pulmonary disease.
Inhibits TNF production in monocytes, reducing inflammatory responses.
Supports SOD and antioxidant gene expression.
Researched as potential agent that may slow cell aging.
Modulates c-Fos and proliferative gene activity.
Dosing Protocols
Available in capsule form for oral administration. As a tripeptide, Chonluten has favorable permeability across cellular compartments. Typical protocol involves 10-20 day cycles.
Standard protocol
10-20 mg
Daily for 10-20 days
Oral capsules
Maintenance
10 mg
2-3 cycles yearly
Interactions
What to Expect
Side Effects & Safety
Common Side Effects
Generally well-tolerated
Minimal side effects reported
Stop Signs - Discontinue if:
Allergic reactions
Unusual respiratory symptoms
Contraindications
Active respiratory emergencies (seek medical care)
Known hypersensitivity
Pregnancy or breastfeeding
Quality Checklist
Good Signs
White powder or capsules
Clear solution if reconstituted
Proper packaging and labeling
Warning Signs
Unknown source or purity
Bad Signs
Discoloration
Unusual odor
Damaged packaging
Frequently Asked Questions
Can Chonluten be taken orally or must it be injected?
Chonluten is available in multiple forms including oral capsules, sublingual, and injectable routes. As a short tripeptide, it has favorable absorption when taken orally (10-20mg daily) or sublingually for enhanced absorption. Most commonly used as a 10-20 day oral cycle, though injectable forms bypass GI metabolism for direct delivery.
How often should Chonluten cycles be repeated?
Standard protocol involves 10-20 day cycles repeated 2-3 times per year with breaks in between. After completing a cycle, effects persist for weeks due to epigenetic changes in gene expression, so spacing cycles allows the body to maintain benefits while avoiding habituation.
Does Chonluten help with chronic respiratory issues like COPD?
Research shows Chonluten has moderate effectiveness for COPD support through TNF inhibition and restoration of lung alveolar tissues. It normalizes respiratory function through gene expression regulation, though it works best as a preventative and maintenance therapy rather than an acute treatment for active respiratory emergencies.
What makes Chonluten different from other immune-supporting peptides?
Chonluten is specifically derived from bronchial lung tissue and targets the respiratory system primarily, unlike broad immune peptides. It regulates genes like c-Fos, HSP70, SOD, and TNF-alpha to reduce inflammatory responses and support lung tissue health, making it unique for respiratory-specific immune modulation.
References
Chonluten tripeptide inhibits TNF production in monocytes exposed to pro-inflammatory LPS.
Chonluten regulates c-Fos, HSP70, SOD, COX-2, and TNF-alpha gene expression.
Short peptides derived from bronchial tissue regulate protein synthesis in lung cells.
Comprehensive review of bioregulator peptides including Chonluten and their mechanisms.
Related Peptides
Related respiratory bioregulators; complementary mechanisms.
Often combined in comprehensive anti-aging Khavinson protocols.
Both have immune-modulating properties; different tissue targets.
Both support mucosal health through different mechanisms.
Disclaimer
This information is for educational and research purposes only. Consult a healthcare professional before use.